Cibus (CBUS) Prices 15.71M Share Offering at $1.75/sh

Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced the pricing of its previously announced public offering of 15,714,285 shares of its Class A Common Stock, at a purchase price of $1.75 per share, including to institutional and strategic investors, as well as the Chairman of Cibus’ board of directors (5,714,286 shares).

All of the shares of Class A Common Stock in the offering will be sold by Cibus. The gross proceeds of the offering are expected to be approximately $27.5 million before deducting placement agent fees and other estimated offering expenses payable by the Company. The offering is expected to be closed on or about June 6, 2025, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to fund further development of the Company’s weed management productivity traits in Rice and for working capital and general corporate purposes, as it pursues longer-term financing.

A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.

This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-273062), including base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on June 30, 2023, and declared effective on October 27, 2023. A prospectus supplement describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Copies of the prospectus supplement and the accompanying base prospectus, when available, may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

You May Also Be Interested In

• enCore Energy launches $250M at-the-market share offering
• Collegium Pharmaceutical launches $50M accelerated share repurchase
• Southland Holdings reaches financing deal with surety partners